Abstract
Objective
The pharmacological profile of escitalopram, the S-(+)-enantiomer of citalopram, was studied and compared with citalopram and the R-(−)-enantiomer, R-citalopram.
Methods
Inhibition of the serotonin transporter (5-HTT) was studied in COS-1 cells expressing the human 5-HTT (h-5-HTT) and in rat brain synaptosomes. In vitro selectivity was studied relative to noradrenaline transporter (NAT) and dopamine transporter (DAT) function in rat brain synaptosomes, and affinities for other binding sites were determined. In vivo 5-HT activity was measured as inhibition of neuronal firing rate in rat dorsal raphe nucleus (DRN) and enhancement of 5-hydroxytryptophan (5-HTP)-induced behaviour (mouse and rat). Furthermore, studies were conducted in models of antidepressant (mouse forced-swim test), anxiolytic [foot-shock-induced ultrasonic vocalization (USV) in adult rats and mouse black and white box] and anti-aggressive activity (socially isolated mice).
Results
Escitalopram inhibited 5-HTT functions approximately 2 times more potently than citalopram and at least 40 times more potently than R-citalopram. Escitalopram showed insignificant activity at other monoamine transporters and 144 other binding sites. Escitalopram inhibited 5-HT neuronal firing in DRN and potentiated 5-HTP-induced behaviours more potently than citalopram; R-citalopram was inactive. Escitalopram and citalopram, but not R-citalopram, reduced forced-swimming-induced immobility and facilitated exploratory behaviour in the black and white box. Escitalopram and citalopram inhibited USV potently; R-citalopram was several times less potent. Escitalopram, citalopram and R-citalopram inhibited aggressive behaviour weakly. Escitalopram and citalopram had very potent anti-aggressive effects when co-administered with l-5-HTP.
Conclusion
Escitalopram is a very selective 5-HT reuptake inhibitor. It is more potent than its racemate citalopram and is effective in animal models predictive of antidepressant and anxiolytic activities.
Similar content being viewed by others
References
Aghajanian GK (1978) Feedback regulation of central monaminergic neurones: evidence from single-cell recording studies. In: Youdim MBH, Lovenberg W, Sharman DF, Lagando JR (eds) Essays in neurochemistry and neuropharmacology. Wiley, New York, pp 1–32
Blier P, de Montigny C (1997) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220–226
Borsini F (1995) Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rev 19:377–395
Borsini F, Meli A (1988) Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94:147–160
Burke WJ, Gergel I, Bose A (2002) Fixed-dose trial of the single isomer SSRI escitalopram in depressed out patients. J Clin Psychiatry 63:331–336
Caldwell J (2002) Do single enantiomers have something special to offer? Hum Psychopharmacol Clin Exp 16:S67–S71
Costall B, Jones BJ, Kelly ME, Naylor RJ, Tomkins DM (1989) Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol Biochem Behav 32:777–785
Crawley J, Goodwin FK (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13:167–170
De Vry J, Benz U, Schreiber R, Traber J (1993) Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anxiolytic drugs. Eur J Pharmacol 249:331–339
Gardner CR (1985) Distress vocalization in rat pups. A simple screening method for anxiolytic drugs. J Pharmacol Methods 14:181–187
Gorman JM, Korotzer A, Su G (2002) Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo controlled trials. CNS Spectrums 7:40–44
Hall H, Ögren SO (1984) Effects of antidepressant drugs on histamine-H1 receptors in the brain. Life Sci 34:597–605
Hyttel J (1982) Citalopram. Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Progr Neuropsychopharmacol Biol Psychiatry 6:177–295
Hyttel J, Bøgesø KP, Perregaard J, Sánchez C (1992) The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neur Transm 88:157–160
Kaltwasser MT (1990) Startle-inducing acoustic stimuli evoke ultrasonic vocalization in the rat. Physiol Behav 48:13–17
Meier E, Frederiksen K, Nielsen M, Lembøl HL, Pedersen H, Hyttel J (1997) Pharmacological in vitro characterization of Lu 25–109-T, a muscarinic compound with M1-agonistic and M2/M3-antagonistic properties. Drug Dev Res 40:1–16
Montgomery SA, Loft H, Sánchez C, Reines EH, Papp M (2001) Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88:282–286
Olivier B, van Oorschot R, Mos J (1998) Rodent models of aggressive behaviour. In: Maes M, Coccaro E (eds) Neurobiology of aggression and impulsivity. Wiley, London, pp 167–182
Owens MJ, Rosenbaum JF (2002) Escitalopram: a second generation SSRI. CNS Spectr 7:34–39
Owens MJ, Knight DL, Nemeroff CB (2001) Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345–350
Porsolt RD, Bertin A, Jalfre M (1977) Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336
Romero L, Bel N, Artigas F, de Montigny C, Blier P (1996) Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 15:349–360
Sánchez C (1993) Effect of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats. Behav Pharmacol 4:269–277
Sánchez C (1995) Serotonergic mechanisms involved in the exploratory behaviour of mice in a fully automated two-compartment black and white test box. Pharmacol Toxicol 77:71–78
Sánchez C (1998) 5-HT1A receptors in the treatment of aggression and impulse control disorders (ICDs). In: Maes M, Coccaro E (eds) Neurobiology of aggression and impulsivity. Wiley, London, pp 181–196
Sánchez C (2003) Stress-induced vocalisation in adult animals. A valid model of anxiety? Eur J Pharmacol (in press)
Sánchez C, Hyttel J (1994) Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT1A receptors. Eur J Pharmacol 264:241–247
Sánchez C, Meier E (1997) Behavioral profile of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology 129:197–205
Sánchez C, Arnt J, Hyttel J, Moltzen EK (1993) The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice. Psychopharmacology 110:53–59
Sánchez C, Arnt J, Costall B, Kelly ME, Meier E, Naylor RJ, Perregaard J (1997) The selective σ2 ligand Lu 28–179 has potent anxiolytic-like effects in rodents. J Pharmacol Exp Ther 283:1343–1353
Schreiber R, Melon C, De Vry J (1998) The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalisation test. Psychopharmacology 135:383–391
Tonoue T, Ashida Y, Makino H, Hata H (1986) Inhibition of shock-elicited ultrasonic vocalization by opioid peptides in the rat: a psychotropic effect. Psychoneuroendocrinology 11:177–184
Wade A, Lemming OM, Hedegaard KB (2002) Escitalopram 10 mg/day is effective and well tolerated in a placebo controlled study in depression in primary care. Int Clin Psychopharmacol 17:95–102
Acknowledgements
The excellent technical assistance of Betina Dobel Frederiksen, Jeanne Jakobsen, Søren Hansen, Bente Ladegaard, Karin Larsen and Dorit Skov is highly appreciated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sánchez, C., Bergqvist, P.B.F., Brennum, L.T. et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167, 353–362 (2003). https://doi.org/10.1007/s00213-002-1364-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-002-1364-z